A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human
epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
The main goals of this study are to:
1. To evaluate the safety and tolerability of AC682
2. To evaluate the pharmacokinetic of AC682
3. To evaluate the preliminary anti-tumor activity of AC682